What is ONI?
Headquartered in Oxford, United Kingdom, ONI specializes in the development and deployment of super-resolution microscopes. The company's core technology enables researchers to visualize biological processes at a level of detail previously unattainable with conventional optical systems. By integrating advanced hardware with sophisticated software, ONI provides a comprehensive platform that supports drug discovery, personalized medicine, and fundamental biological research. Their market position is defined by a commitment to democratizing high-end imaging, making complex microscopy accessible to a broader range of academic and commercial laboratories.
How much funding has ONI raised?
ONI has raised a total of $76.7M across 2 funding rounds:
Angel/Seed
$1.7M
Series B
$75M
Angel/Seed (2016): $1.7M with participation from Oxford Technology Management and Oxford Sciences Enterprises
Series B (2022): $75M led by Artis Ventures Management Iii, Vertical Venture Partners, Section 32, ARCH Venture Partners, and Casdin Capital
Key Investors in ONI
Artis Ventures Management Iii
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness.
Vertical Venture Partners
Vertical Venture Partners is an early-stage venture capital firm that focuses on investing in enterprise technology companies targeting specific vertical markets.
Section 32
S32 | Venture Beyond is a venture capital firm that focuses on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of technological advancement.
What's next for ONI?
With the recent influx of capital, ONI is well-positioned to scale its commercial operations and deepen its R&D capabilities. The strategic focus will likely shift toward enhancing the throughput of its imaging platforms and expanding its footprint in the North American and Asian markets. As the company transitions into a more mature enterprise phase, the emphasis will remain on fostering partnerships with pharmaceutical giants and academic institutions to integrate their microscopy solutions into standard drug development workflows. This strategic pivot aims to capitalize on the increasing intersection of AI-driven data analysis and high-resolution biological imaging, ensuring ONI remains at the forefront of the biotech revolution.
See full ONI company page
